MigraineNCT07250464
Motor Evoked Potential and Cortical Silent Period in Migraine
A study testing Transcranial Magnetic Stimulation (TMS), Surface Electromyography (sEMG) and Needle EMG / Single Motor Unit (SMU) Recording in people with Migraine and Healty Controls, run by Istanbul Gelisim University at 1 site in Turkey (Türkiye).
Trial summary
The primary objective of this study is to assess the level of inhibitory control in the motor cortex of migraine patients using objective and non-invasive methods. To this end, Motor Evoked Potential (MEP) and Cortical Silence Period (CSP) parameters obtained using Transcranial Magnetic Stimulation (TMS) will be… Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Migraine, Healty Controls
- What is being tested?
- Transcranial Magnetic Stimulation (TMS), Surface Electromyography (sEMG) and Needle EMG / Single Motor Unit (SMU) Recording
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Dec 2025to 1 Feb 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age 18-45 years.
- Right-handed individuals.
- Migraine patients: diagnosed according to International Headache Society (IHS) criteria.
- Healthy controls: no history of migraine or other neurological disorders.
- Able and willing to provide informed consent.
Who cannot join
- History of epilepsy or other seizure disorders.
- Presence of metal implants, pacemakers, or other contraindications to TMS.
- Pregnancy or breastfeeding.
- History of significant neurological or psychiatric disorders.
- Use of medications that significantly alter cortical excitability (e.g., antiepileptics, benzodiazepines) in the last 2 weeks.
- Any musculoskeletal condition preventing safe participation in EMG/TMS procedures.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site
Istanbul Gelisim University, Faculty of Dentistry, Translational Dentistry Research Laboratory
Istanbul, Istanbul, 34310
Murat Kara, MSc, +905314708141, murkara@gelisim.edu.tr
Kemal Sıtkı Türker, Prof. Dr., +905325987791, ksturker@gelisim.edu.tr
About this study
Official title: Investigation of Motor Evoked Potential and Cortical Silent Period in Migraine Patients
The primary objective of this study is to assess the level of inhibitory control in the motor cortex of migraine patients using objective and non-invasive methods. To this end, Motor Evoked Potential (MEP) and Cortical Silence Period (CSP) parameters obtained using Transcranial Magnetic Stimulation (TMS) will be measured and comparisons will be made between migraine patients and healthy controls. Since CSP duration is used specifically in the evaluation of GABA-B-mediated inhibitory mechanisms, it has the potential to directly measure the effect of migraine on cortical inhibition.
Read the detailed description
Rationale and Background:
Migraine is a neurological disorder that significantly impairs individual quality of life and imposes substantial economic burdens on healthcare systems worldwide. Although its pathophysiology is not fully understood, recent research suggests that migraine is associated not only with vascular changes but also with alterations at neurological and cortical levels (Goadsby et al., 2017). Evidence increasingly indicates enhanced excitability and disrupted inhibitory mechanisms in central nervous system regions, including the motor cortex (Coppola et al., 2007).
Transcranial Magnetic Stimulation (TMS) is a non-invasive and reliable neurophysiological technique that stimulates the motor cortex and records muscle responses. Parameters obtained through TMS, such as Motor Evoked Potential (MEP) and Cortical Silent Period (CSP), are used to assess cortical excitability and inhibitory control, respectively (Chen et al., 1999). CSP is particularly useful for evaluating GABA-B-mediated inhibitory mechanisms. The hypothesis that migraine patients exhibit reduced cortical inhibition can be directly tested using CSP measurements.
Previous studies have reported shortened CSP durations and increased MEP amplitudes in migraine patients, suggesting cortical hyperexcitability (Brighina et al., 2002; Afra et al., 1998). However, these findings are inconsistent, and how they vary across migraine subtypes (with aura vs. without aura) remains unclear. Therefore, this study aims to characterize cortical physiological changes in migraine using objective and quantitative measures, filling gaps in the literature and contributing to clinical evaluations. Additionally, the relationship of these parameters with clinical features such as migraine type, duration, and attack frequency will be investigated to lay the groundwork for individualized neurophysiological profiling.
Primary and Secondary Objectives:
Primary Objective:
The primary objective of this study is to objectively evaluate inhibitory control in the motor cortex of migraine patients using non-invasive methods. Motor Evoked Potentials (MEP) and Cortical Silent Periods (CSP) obtained through TMS will be measured and compared between migraine patients and healthy controls. CSP duration, reflecting GABA-B-mediated inhibitory mechanisms, allows direct assessment of migraine's effect on cortical inhibition (Chen et al., 1999).
Secondary Objectives:
Motor Output Analysis: Electromyographic (EMG) signals will be analyzed using Peristimulus Time Histogram (PSTH) and Peristimulus Frequencygram (PSF) methods to assess the temporal pattern and frequency changes of motor unit responses following TMS. PSTH analyzes the timing of individual motor units after stimulation, while PSF provides a more precise view of post-stimulation frequency changes (Türker \& Powers, 2001). These analyses help reveal the spinal reflection of cortical stimulation and its effect on motor output.
Biomarker Potential: TMS-derived parameters such as CSP and MEP will be evaluated for their potential as biomarkers of migraine pathophysiology, contributing to the development of objective measures for future diagnosis and treatment.
Expected Benefits:
At the end of this study, it is expected to obtain objective data on motor cortical inhibitory capacity in migraine patients. TMS parameters, particularly CSP and MEP, can be used to understand the neurophysiological basis of migraine. The results may provide:
Improved understanding of cortical excitability and inhibition balance in migraine pathophysiology.
Foundational data for the development of objective diagnostic biomarkers for migraine.
Evidence of cortical dysfunction in migraine patients, supporting personalized treatment approaches.
A comprehensive understanding of motor output from cortical to spinal levels via electrophysiological analyses (PSTH/PSF).
All procedures are non-invasive and safe, providing a reproducible and ethical research approach.
Study Methods:
Participants:
The study will include right-handed individuals aged 18-45 years with a prior diagnosis of migraine according to the International Headache Society (IHS) criteria.
Data Collection:
The study will use non-invasive brain stimulation (TMS) along with surface electromyography (sEMG) and needle EMG. Measurements will be performed both at rest and during voluntary muscle contraction. TMS will be applied over the motor cortex, and muscle responses will be recorded simultaneously using sEMG electrodes. For detailed motor neuron analysis, single motor unit (SMU) recordings will also be obtained.
Needle EMG/SMU Recording:
SMU recordings will use sterile, Teflon-coated needles containing copper wires (approximately 70 μm diameter, 25G) inserted into the first dorsal interosseous (FDI) muscle. Needles will be partially retracted to maintain electrode stability, allowing single motor unit activity to be recorded even during movement.
TMS Application:
TMS will be performed using a Magstim 200^2 Monophasic Stimulator (Magstim Ltd, UK) with a 70 mm figure-of-eight coil placed over the dominant hemisphere's primary motor cortex (M1) corresponding to the FDI muscle. Resting Motor Threshold (RMT) will be determined, followed by stimulation to elicit MEPs.
Surface EMG Recording:
sEMG signals will be obtained using Ag/AgCl electrodes placed over the FDI muscle. Signals will be amplified with a CED 1902 amplifier and digitized via CED 3601 Power 1401 DAC unit. MEP latencies and amplitudes, as well as CSP durations, will be calculated. Participants will maintain ~20% maximal voluntary contraction during measurements.
Data Analysis:
Data will be analyzed using IBM SPSS Statistics 26. Normality will be tested using Kolmogorov-Smirnov and Shapiro-Wilk tests. Parametric data will be analyzed using independent t-tests and ANOVA, while non-parametric data will be analyzed with Mann-Whitney U or Kruskal-Wallis tests. Correlations between clinical parameters (migraine duration, frequency, severity) and neurophysiological measures (MEP, CSP) will be assessed using Pearson or Spearman correlation coefficients, with significance set at p < 0.05.
- Conditions
- Migraine, Healty Controls
- Being tested
- Transcranial Magnetic Stimulation (TMS), Surface Electromyography (sEMG), Needle EMG / Single Motor Unit (SMU) Recording
- Keywords
- cortical silent period, migraine, single motor unit, transcranial magnetic stimulation
- Medical subject headings
- Migraine Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transcranial Magnetic Stimulation (TMS)Other
Non-invasive brain stimulation applied to the primary motor cortex to elicit motor evoked potentials (MEP) and cortical silent periods (CSP).
70 mm figure-of-eight coil used with Magstim 200² Monophasic Stimulator.
Surface Electromyography (sEMG)Device
Bipolar Ag/AgCl electrodes placed over the first dorsal interosseous (FDI) muscle to record muscle responses to TMS.
Needle EMG / Single Motor Unit (SMU) RecordingOther
Sterile Teflon-coated needle electrodes inserted into the FDI muscle to record activity of individual motor units during TMS and voluntary contractions.
| Study group | Role | What they receive |
|---|---|---|
| Migraine Patients | Experimental | Adult participants aged 18-45 with a prior diagnosis of migraine according to IHS criteria.
Transcranial Magnetic Stimulation (TMS)
Surface Electromyography (sEMG)
Needle EMG / Single Motor Unit (SMU) Recording Receives: Other: Transcranial Magnetic Stimulation (TMS); Device: Surface Electromyography (sEMG); Other: Needle EMG / Single Motor Unit (SMU) Recording |
| Healthy Controls | Sham comparator | Age- and sex-matched adults without a history of migraine or neurological disorders.
They undergo the same sEMG and needle EMG/SMU procedures as the migraine group, but the TMS is sham.
Surface Electromyography (sEMG)
Needle EMG / Single Motor Unit (SMU) Recording
Transcranial Magnetic Stimulation (TMS) SHAM Receives: Device: Surface Electromyography (sEMG); Other: Needle EMG / Single Motor Unit (SMU) Recording |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cortical Silent Period (CSP) Duration
CSP duration will be recorded from the first dorsal interosseous (FDI) muscle using surface EMG during TMS. CSP reflects GABA-B-mediated cortical inhibitory mechanisms, allowing direct assessment of cortical inhibition in migraine patients compared to healthy controls.
Measured: Single session measurement during TMS
Secondary outcomes (1)
Motor Evoked Potential (MEP) Amplitude
MEP amplitudes will be recorded from FDI muscle using surface EMG. Changes in MEP amplitude reflect cortical excitability and motor output.
Measured: Single session measurement during TMS
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Nov 2025
- Study start1 Dec 2025 (estimated)
- Primary completion1 Jan 2026 (estimated)
- Study completion1 Feb 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for MigraineStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Two groups (migraine patients and healthy controls) are evaluated in parallel. Participants and the responsible investigators are blinded to group assignments to reduce bias. Only the staff performing TMS and EMG measurements are aware of group allocation.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Istanbul Gelisim University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Kemal Sıtkı Türker, Prof. Dr., Principal investigator, Istanbul Gelisim University, Faculty of Dentistry, Translational Dentistry Research Laboratory
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07250464
- Sponsor's protocol ID
- IGU-ENF-MK-1
- Status last verified
- Nov 2025
- First submitted
- 14 Nov 2025
- Last updated
- 28 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (EMG and TMS measurements) will not be shared outside of the published study results to protect participant confidentiality and privacy.
Publications
Haavik H, Niazi IK, Jochumsen M, Ugincius P, Sebik O, Yilmaz G, Navid MS, Ozyurt MG, Turker KS. Chiropractic spinal manipulation alters TMS induced I-wave excitability and shortens the cortical silent period. J Electromyogr Kinesiol. 2018 Oct;42:24-35. doi: 10.1016/j.jelekin.2018.06.010. Epub 2018 Jun 19.
PubMed 29936314Ozyurt MG, Haavik H, Nedergaard RW, Topkara B, Senocak BS, Goztepe MB, Niazi IK, Turker KS. Transcranial magnetic stimulation induced early silent period and rebound activity re-examined. PLoS One. 2019 Dec 4;14(12):e0225535. doi: 10.1371/journal.pone.0225535. eCollection 2019.
PubMed 31800618Todd G, Rogasch NC, Turker KS. Transcranial magnetic stimulation and peristimulus frequencygram. Clin Neurophysiol. 2012 May;123(5):1002-9. doi: 10.1016/j.clinph.2011.09.019. Epub 2011 Oct 22.
PubMed 22019353Haavik, H., Özyurt, M. G., Niazi, I. K., Nedergaard, R. W., Topkara, B., Yilmaz, G., & Türker, K. S. (2018). Re-investigation on the nature and sign of transcranial magnetic stimulation-induced cortical silent period. In 11th Biennial Meeting of the International Motoneuron Society, IBS, 11-14 June 2018, Boulder, CO, USA (pp. 28-29). Article 46 https://motoneuron2018.org/wp-content/uploads/2018/05/IMS-Poster-Abstracts-2018.pdf
Kahya MC, Yavuz SU, Turker KS. Cutaneous silent period in human FDI motor units. Exp Brain Res. 2010 Sep;205(4):455-63. doi: 10.1007/s00221-010-2380-6. Epub 2010 Aug 8.
PubMed 20694723
Study at a glance
From the registry record, last updated by the sponsor on 28 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of Motor Evoked Potential and Cortical Silent Period in Migraine Patients
- ClinicalTrials.gov ID
- NCT07250464
- Acronym / sponsor ID
- IGU-ENF-MK-1
- Conditions
- Migraine, Healty Controls
- Keywords
- cortical silent period, migraine, single motor unit, transcranial magnetic stimulation
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Istanbul Gelisim UniversityUniversity, hospital or other
- Study start
- 1 Dec 2025 (estimated)
- Primary completion
- 1 Jan 2026 (estimated)
- Study completion
- 1 Feb 2026 (estimated)
- First posted
- 26 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to assess the level of inhibitory control in the motor cortex of migraine patients using objective and non-invasive methods. To this end, Motor Evoked Potential (MEP) and Cortical Silence Period (CSP) parameters obtained using Transcranial Magnetic Stimulation (TMS) will be measured and comparisons will be made between migraine patients and healthy controls. Since CSP duration is used specifically in the evaluation of GABA-B-mediated inhibitory mechanisms, it has the potential to directly measure the effect of migraine on cortical inhibition.
Detailed description
Rationale and Background:
Migraine is a neurological disorder that significantly impairs individual quality of life and imposes substantial economic burdens on healthcare systems worldwide. Although its pathophysiology is not fully understood, recent research suggests that migraine is associated not only with vascular changes but also with alterations at neurological and cortical levels (Goadsby et al., 2017). Evidence increasingly indicates enhanced excitability and disrupted inhibitory mechanisms in central nervous system regions, including the motor cortex (Coppola et al., 2007).
Transcranial Magnetic Stimulation (TMS) is a non-invasive and reliable neurophysiological technique that stimulates the motor cortex and records muscle responses. Parameters obtained through TMS, such as Motor Evoked Potential (MEP) and Cortical Silent Period (CSP), are used to assess cortical excitability and inhibitory control, respectively (Chen et al., 1999). CSP is particularly useful for evaluating GABA-B-mediated inhibitory mechanisms. The hypothesis that migraine patients exhibit reduced cortical inhibition can be directly tested using CSP measurements.
Previous studies have reported shortened CSP durations and increased MEP amplitudes in migraine patients, suggesting cortical hyperexcitability (Brighina et al., 2002; Afra et al., 1998). However, these findings are inconsistent, and how they vary across migraine subtypes (with aura vs. without aura) remains unclear. Therefore, this study aims to characterize cortical physiological changes in migraine using objective and quantitative measures, filling gaps in the literature and contributing to clinical evaluations. Additionally, the relationship of these parameters with clinical features such as migraine type, duration, and attack frequency will be investigated to lay the groundwork for individualized neurophysiological profiling.
Primary and Secondary Objectives:
Primary Objective:
The primary objective of this study is to objectively evaluate inhibitory control in the motor cortex of migraine patients using non-invasive methods. Motor Evoked Potentials (MEP) and Cortical Silent Periods (CSP) obtained through TMS will be measured and compared between migraine patients and healthy controls. CSP duration, reflecting GABA-B-mediated inhibitory mechanisms, allows direct assessment of migraine's effect on cortical inhibition (Chen et al., 1999).
Secondary Objectives:
Motor Output Analysis: Electromyographic (EMG) signals will be analyzed using Peristimulus Time Histogram (PSTH) and Peristimulus Frequencygram (PSF) methods to assess the temporal pattern and frequency changes of motor unit responses following TMS. PSTH analyzes the timing of individual motor units after stimulation, while PSF provides a more precise view of post-stimulation frequency changes (Türker \& Powers, 2001). These analyses help reveal the spinal reflection of cortical stimulation and its effect on motor output.
Biomarker Potential: TMS-derived parameters such as CSP and MEP will be evaluated for their potential as biomarkers of migraine pathophysiology, contributing to the development of objective measures for future diagnosis and treatment.
Expected Benefits:
At the end of this study, it is expected to obtain objective data on motor cortical inhibitory capacity in migraine patients. TMS parameters, particularly CSP and MEP, can be used to understand the neurophysiological basis of migraine. The results may provide:
Improved understanding of cortical excitability and inhibition balance in migraine pathophysiology.
Foundational data for the development of objective diagnostic biomarkers for migraine.
Evidence of cortical dysfunction in migraine patients, supporting personalized treatment approaches.
A comprehensive understanding of motor output from cortical to spinal levels via electrophysiological analyses (PSTH/PSF).
All procedures are non-invasive and safe, providing a reproducible and ethical research approach.
Study Methods:
Participants:
The study will include right-handed individuals aged 18-45 years with a prior diagnosis of migraine according to the International Headache Society (IHS) criteria.
Data Collection:
The study will use non-invasive brain stimulation (TMS) along with surface electromyography (sEMG) and needle EMG. Measurements will be performed both at rest and during voluntary muscle contraction. TMS will be applied over the motor cortex, and muscle responses will be recorded simultaneously using sEMG electrodes. For detailed motor neuron analysis, single motor unit (SMU) recordings will also be obtained.
Needle EMG/SMU Recording:
SMU recordings will use sterile, Teflon-coated needles containing copper wires (approximately 70 μm diameter, 25G) inserted into the first dorsal interosseous (FDI) muscle. Needles will be partially retracted to maintain electrode stability, allowing single motor unit activity to be recorded even during movement.
TMS Application:
TMS will be performed using a Magstim 200^2 Monophasic Stimulator (Magstim Ltd, UK) with a 70 mm figure-of-eight coil placed over the dominant hemisphere's primary motor cortex (M1) corresponding to the FDI muscle. Resting Motor Threshold (RMT) will be determined, followed by stimulation to elicit MEPs.
Surface EMG Recording:
sEMG signals will be obtained using Ag/AgCl electrodes placed over the FDI muscle. Signals will be amplified with a CED 1902 amplifier and digitized via CED 3601 Power 1401 DAC unit. MEP latencies and amplitudes, as well as CSP durations, will be calculated. Participants will maintain ~20% maximal voluntary contraction during measurements.
Data Analysis:
Data will be analyzed using IBM SPSS Statistics 26. Normality will be tested using Kolmogorov-Smirnov and Shapiro-Wilk tests. Parametric data will be analyzed using independent t-tests and ANOVA, while non-parametric data will be analyzed with Mann-Whitney U or Kruskal-Wallis tests. Correlations between clinical parameters (migraine duration, frequency, severity) and neurophysiological measures (MEP, CSP) will be assessed using Pearson or Spearman correlation coefficients, with significance set at p < 0.05.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Two groups (migraine patients and healthy controls) are evaluated in parallel. Participants and the responsible investigators are blinded to group assignments to reduce bias. Only the staff performing TMS and EMG measurements are aware of group allocation.
| Arm | Type | Receives |
|---|---|---|
| Migraine Patients | Experimental | Other: Transcranial Magnetic Stimulation (TMS), Device: Surface Electromyography (sEMG), Other: Needle EMG / Single Motor Unit (SMU) RecordingAdult participants aged 18-45 with a prior diagnosis of migraine according to IHS criteria. Transcranial Magnetic Stimulation (TMS) Surface Electromyography (sEMG) Needle EMG / Single Motor Unit (SMU) Recording |
| Healthy Controls | Sham comparator | Device: Surface Electromyography (sEMG), Other: Needle EMG / Single Motor Unit (SMU) RecordingAge- and sex-matched adults without a history of migraine or neurological disorders. They undergo the same sEMG and needle EMG/SMU procedures as the migraine group, but the TMS is sham. Surface Electromyography (sEMG) Needle EMG / Single Motor Unit (SMU) Recording Transcranial Magnetic Stimulation (TMS) SHAM |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Age 18-45 years.
- Right-handed individuals.
- Migraine patients: diagnosed according to International Headache Society (IHS) criteria.
- Healthy controls: no history of migraine or other neurological disorders.
- Able and willing to provide informed consent.
Key exclusion criteria (6 listed)
- History of epilepsy or other seizure disorders.
- Presence of metal implants, pacemakers, or other contraindications to TMS.
- Pregnancy or breastfeeding.
- History of significant neurological or psychiatric disorders.
- Use of medications that significantly alter cortical excitability (e.g., antiepileptics, benzodiazepines) in the last 2 weeks.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transcranial Magnetic Stimulation (TMS)Non-invasive brain stimulation applied to the primary motor cortex to elicit motor evoked potentials (MEP) and cortical silent periods (CSP). 70 mm figure-of-eight coil used with Magstim 200² Monophasic Stimulator. | Other | Migraine Patients |
| Surface Electromyography (sEMG)Bipolar Ag/AgCl electrodes placed over the first dorsal interosseous (FDI) muscle to record muscle responses to TMS. | Device | Healthy Controls, Migraine Patients |
| Needle EMG / Single Motor Unit (SMU) RecordingSterile Teflon-coated needle electrodes inserted into the FDI muscle to record activity of individual motor units during TMS and voluntary contractions. | Other | Healthy Controls, Migraine Patients |
Primary outcome
Cortical Silent Period (CSP) Duration
Time frame: Single session measurement during TMS
CSP duration will be recorded from the first dorsal interosseous (FDI) muscle using surface EMG during TMS. CSP reflects GABA-B-mediated cortical inhibitory mechanisms, allowing direct assessment of cortical inhibition in migraine patients compared to healthy controls.
1 secondary outcome
Motor Evoked Potential (MEP) Amplitude
Time frame: Single session measurement during TMS
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Nov 2025.
- Background: PubMed 29936314Haavik H, Niazi IK, Jochumsen M, Ugincius P, Sebik O, Yilmaz G, Navid MS, Ozyurt MG, Turker KS. Chiropractic spinal manipulation alters TMS induced I-wave excitability and shortens the cortical silent period. J Electromyogr Kinesiol. 2018 Oct;42:24-35. doi: 10.1016/j.jelekin.2018.06.010. Epub 2018 Jun 19.
- Background: PubMed 31800618Ozyurt MG, Haavik H, Nedergaard RW, Topkara B, Senocak BS, Goztepe MB, Niazi IK, Turker KS. Transcranial magnetic stimulation induced early silent period and rebound activity re-examined. PLoS One. 2019 Dec 4;14(12):e0225535. doi: 10.1371/journal.pone.0225535. eCollection 2019.
- Background: PubMed 22019353Todd G, Rogasch NC, Turker KS. Transcranial magnetic stimulation and peristimulus frequencygram. Clin Neurophysiol. 2012 May;123(5):1002-9. doi: 10.1016/j.clinph.2011.09.019. Epub 2011 Oct 22.
- BackgroundHaavik, H., Özyurt, M. G., Niazi, I. K., Nedergaard, R. W., Topkara, B., Yilmaz, G., & Türker, K. S. (2018). Re-investigation on the nature and sign of transcranial magnetic stimulation-induced cortical silent period. In 11th Biennial Meeting of the International Motoneuron Society, IBS, 11-14 June 2018, Boulder, CO, USA (pp. 28-29). Article 46 https://motoneuron2018.org/wp-content/uploads/2018/05/IMS-Poster-Abstracts-2018.pdf
- Background: PubMed 20694723Kahya MC, Yavuz SU, Turker KS. Cutaneous silent period in human FDI motor units. Exp Brain Res. 2010 Sep;205(4):455-63. doi: 10.1007/s00221-010-2380-6. Epub 2010 Aug 8.
- No public protocol page available; contact murkara@gelisim.edu.tr for study information.Link provided by the sponsor.
- Individual participant dataSharing planned: No. Individual participant data (EMG and TMS measurements) will not be shared outside of the published study results to protect participant confidentiality and privacy.
Related trials for Migraine
RecruitingObservational study
Study of the Glymphatic System in Migraine
Migraine
Active, not recruiting
Clinical and Neurophysiological Effects of tDCS to Visual and Motor Cortex in Migraine
Migraine
Active, not recruiting
App-Based Migraine Treatment: The Health enSuite Study
Migraine, Migraine With Aura
Not yet recruiting
A Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare Professionals
Migraine Disorders
Recruiting
Marine Lipids Ease Painful TMD
Temporomandibular Disorder (TMD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Kemal Sıtkı Türker, Prof. Dr. principal investigator
Istanbul Gelisim University, Faculty of Dentistry, Translational Dentistry Research Laboratory
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Transcranial Magnetic Stimulation (TMS), Surface Electromyography (sEMG) and Needle EMG / Single Motor Unit (SMU) Recording in people with Migraine and Healty Controls, run by Istanbul Gelisim University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 28 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Murat Kara, MSc (+905314708141, murkara@gelisim.edu.tr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cortical Silent Period (CSP) Duration (time frame: Single session measurement during TMS). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07250464, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Nov 2025.